

## DAFTAR PUSTAKA

- American Cancer Society Incorporation. (2014). *Cancer Facts & Figures 2015*. In *Who* (pp. 1–64). <https://doi.org/10.1002/ijc.27711>
- Andrijono. (2010). *Kanker Serviks Ed. 3*. Jakarta: Divisi Onkologi Departemen Obstetri dan Ginekologi FK UI 810
- Ariani, Sofi. (2015). *Stop Kanker*. Yogyakarta: Istana Media.
- Badan Pusat Statistik.(2010). *Data Statistik Indonesia. Jumlah Penduduk menurut Kelompok Umur, Jenis Kelamin, Provinsi, dan Kabupaten/Kota, 2005*. Diakses pada tanggal 29 April 2015. Dari <http://demografi.bgs.go.id/>
- Bagian Rekam Medik RSUD Prof. Dr Margono Soekarjo, (2017).
- Bernabé, M. et al. (2010). Recurrent cervical cancer: Where to look for them Poster. *European Society of Radiology DOI: 10.1594/ecr2010/C-1207*.
- Boussios, S. et al. (2016). *Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review*. Department of Medical Oncology, Medical School, University of Ioannina, Greece. <http://dx.doi.org/10.1016/j.critrevonc.2016.11.006>
- Compton JJ, Gaspar LE, Shrieve DC, et al. *Resident-reported brachytherapy experience in ACGME-accredited radiation oncology training programs*. *Brachytherapy* 2013:12
- Choi, J. et al. (2008). The efficacy of concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for locally advanced cancer of the uterine cervix. *J Gynecol Oncol Vol. 19, No. 2:129-134, June 2008 DOI:10.3802/jgo.2008.19.2.129*.
- Dantes, N. (2012). *Metode Penelitian*. Yogyakarta: CV Andi Offset.
- Darayani, MD., Sumawati, NMR. (2013). *Hubungan Umur dengan Kejadian Ca. Serviks di Laboratorium Patologi Anatomi RSUP Sanglah*. *Dunia Kesehatan*, Vol.2, No. 2. (Hlm. 1-10).
- Davey, P. (2006). *At a Glance Medicine*. diterjemahkan oleh Annisa, R., & Cut, N.R.. Erlangga. Surabaya.

- Departemen Kesehatan RI. (2012). *Riset Kesehatan Dasar Tahun 2012*. Penelitian dan Pengembangan Kesehatan Departemen Kesehatan RI. Jakarta: Badan Litbangkes RI 2012.
- Depkes.(2015). *Situasi Penyakit Kanker*. Diakses pada tanggal 10 November 2017 dari <http://www.depkes.go.id/download.php?file=download/pusdatin/infoatin/infodatin-kanker.pdf>. Diakses pada tanggal 2 Oktober 2017
- Depkes RI. (2015). Infodatin : *Stop Kanker*, diambil dari <http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin-kanker.pdf> yang diakses tanggal 10 November 2017. Jakarta : Pusat data dan informasi kementerian kesehatan RI.
- Dewi, NML, (2013). *Hubungan Tingkat Pengetahuan Dan Sikap Wanita Usia Subur (WUS) Dengan Pemeriksaan Inspeksi Visual Asam Asetat (IVA) Di Puskesmas Buleleng I*. Jurnal Keperawatan Maternitas. Volume 1, No. 1, Mei 2013: 55-60.
- Dipiro, J.T., Wells, B.G., Schwinghammer, T.L., dan Dipiro. C.V. (2009). *Pharmacoterapy Handbook Seventh Edition*. 532-533. McGraw-Hill Medical : New York.
- Fatemeh, G. et al. (2012). Risk Factors and Clinical Aspects of Recurrent Invasive Cervical Carcinoma. *The Journal of Obstetrics and Gynecology of India (November–December 2012)* 62(6):674–678.
- FIGO Committee on Gynecologic Oncology. (2000). Staging classifications and clinical practice guidelines of gynaecologic cancers. *Reprinted from International journal of Gynecology and Obstetrics* 70 (2000) 207-312.
- Fitriana, A., and Ambarini. (2012). *Kualitas Hidup Pada Penderita Kanker Serviks Yang Menjalani Pengobatan Radioterapi*. Surabaya : Fakultas Psikologi Universitas Airlangga Surabaya.
- Gao, Yin. et al. (2013). The evaluation of older patientswith cervical cancer. *Clinical Interventions in Aging* 2013:8 783–788.

- Globocan-IARC. (2014). *Estimated cancer incidence, mortality and prevalence worldwide in 2012*. International Agency for Research on Cancer, World Health Organization. [http://globocan.iarc.fr/Pages/fact\\_sheets\\_cancer.aspx](http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx). [29 Oktober 2017].
- Herlana, F., Nur, M. dan Purbaningsih, W. (2017). Karakteristik Pasien Kanker Serviks berdasar atas Usia, Paritas, dan Gambaran Histopatologi di RSUD Al-Ihsan Bandung. *Bandung Meeting on Global Medicine & Health (BaMGMH), Vol. 1 No. 1 Tahun 2017*.
- IARC, Globocan. (2012). *Estimated Cancer Incidence, Mortality and Prevalence Worldwide In 2012*. diambil dari <http://globocan.iarc.fr/Default.aspx> yang diakses tanggal 22 November 2017.
- Nurjamilah, L. (2014). Cost Effectiveness Analysis terapi kanker serviks dengan menggunakan CDC dan cisplatin tunggal di RSUD Prof. Dr. Margono Soekarjo. UMP: Purwokerto.
- JW, D., FD, G., BJ, M., & DW, L. (2015). *Strategic framework for the comprehensive control of cancer cervix in South-East Asia Region*. *MMWR. Morbidity and Mortality Weekly Report* (Vol. 64).
- Kemenkes. (2013). *Riset Kesehatan Dasar: Riskesdas 2013*, Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI 2013, Jakarta.
- Kemenkes RI. (2015). InfoDATIN Pusat Data dan Informasi Kementerian Kesehatan RI: *Stop Kanker*. Diakses 29 Oktober 2017 dari <http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin-kanker.pdf>.
- Kemenkes RI. (2015). *Panduan Program Nasional Gerakan Pencegahan dan Deteksi Dini Kanker. Kanker Leher Rahim dan Kanker Payudara*. Jakarta: Kementerian Kesehatan RI, Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Direktorat Pengendalian Penyakit Tidak Menular.
- Kementerian Kesehatan RI. (2015). *Panduan Penatalaksanaan Kanker Serviks*. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan RI.

- Kostova, P., Zlatkov, V. and Danon, S. (2008). Five-year overall survival and prognostic factors in patients with cervical cancer in Bulgaria. *Journal of BUON* 13: 363-368, 200.
- Lanceley, A. et al. (2013). Follow-up protocols for women with cervical cancer after primary treatment (Review). *Cochrane Database of Systematic Reviews* 2013, Issue 11. Art.No.: CD008767. DOI: 10.1002/14651858.CD008767.pub2.
- Lasut, E., Rarung, M. dan Suparman, E. (2015). Karakteristik Penderita Kanker Serviks Di Blu RSUP Prof. Dr. R. D. Kandou. *Jurnal e-Clinic (eCl)*, Volume 3, Nomor 1, Januari-April 2015.
- Lee, Y. et al. (2017). Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation. *ONCOLOGY LETTERS* 14: 73-78, 2017 DOI: 10.3892/ol.2017.6117Abstract.
- Misgiyanto dan Susilawati, D. (2014). Hubungan Antara Dukungan Keluarga Dengan Tingkat Kecemasan Penderita Kanker Serviks Paliatif. *Jurnal Keperawatan*, ISSN: 2086-3071 Volume 5, Nomor 1, Januari 2014 : 01 - 15.
- Morice, P. et al. (2004). Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery–radiation therapy. *Annals of Oncology* 15: 218–223, 2004 DOI: 10.1093/annonc/mdh050.
- Nadya, G. et al., (2017). Gambaran Kualitas Hidup Pasien Kanker Stadium Lanjut Yang Menjalani Radioterapi Paliatif Di RSUD Arifin Achmad Provinsi Riau. Riau : RSUD Arifin Achmad Provinsi Riau
- Notoatmodjo, S. (2012). *Metodologi Penelitian Kesehatan*. Jakarta: Rineka Cipta.
- Nowakowski, A. et al. (2016) . Cervical Cancer Histology, Staging and Survival before and after Implementation of Organised Cervical Screening Programme in Poland. *PLOS ONE* DOI:10.1371/journal.pone.0155849 May 19, 2016.
- Peraturan Presiden Republik Indonesia Nomor 111 Tahun 2013 Tentang Perubahan Atas Peraturan Presiden Nomor 12 Tahun 2013 Tentang *Jaminan Kesehatan*. Jakarta

- Prawiroharjo, S. (2010). *Onkologi Ginekologi, Edisi 1 dalam*. Jakarta: Yayasan Bina Pustaka.
- Price S.A. dan Wilson, L.M. (2003). *Patofisiologi : Konsep Klinis Proses-Proses Penyakit*. 6th ed. Penerbit Buku Kedokteran EGC, Jakarta.
- Rasjidi, I. (2008). *Manual Prakanker Serviks*. Jakarta : CV Sagung Seto
- Rasjidi, I. (2010). *100 Question & Answer Kanker Pada Wanita*. PT Elex Media Komputindo : Jakarta.
- (RISKESDAS), R. K. D. (2013). Riset Kesehatan Dasar (RISKESDAS) 2013. *Laporan Nasional 2013*, 1–384. <https://doi.org/10.24063/riskesdas2013>.
- Rose, P. G., & Lappas, P. T. (2000). Analysis of the Cost Effectiveness of Concurrent Cisplatin-Based Chemoradiation in Cervical Cancer: Implications from Five Randomized Trials. *Gynecologic Oncology*, 78(1), 3–6. <https://doi.org/10.1006/gyno.2000.5810>.
- Setiawan, D. (2017). *Farmakoekonomi Modeling*. UMP Pres : Purwokerto
- Sirait, M., Soetiarto, F. dan Oemiati, R. (2003). Ketahanan Hidup Penderita Kanker Serviks di Rumah Sakit Kanker Dharmais, Jakarta. *Badan Litbangkes Bul. Penel. Kesehatan Vol. 31, No. 1, 2003: 13-24*.
- Sol, S. E. et al. (2009). Comparison of concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil versus cisplatin plus paclitaxel in patients with locally advanced cervical carcinoma. *J Gynecol Oncol Vol. 20, No. 1:28-34, March 2009 DOI:10.3802/jgo.2009.20.1.28*.
- Syatriani, S. (2011). Risk Factor of Cervical Cancer in Dr. Wahidin Sudirohusodo Government General Hospital Makassar, South Sulawesi. *Jurnal Kesehatan Masyarakat Nasional Vol. 5 No. 6, Juni 2011*.
- Tay SK, Tay KJ,. (2004). *Passive Cigarette Smoking is a Risk Factor in Cervical Neoplasia, Gynecol Oncol, Vol. 20. hlm 93-116*
- Takekuma, M. et al. (2015). Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer. *J Gynecol Oncol Vol. 26, No. 3:185-192*.
- Trask, L.S,. (2011). *Pharmacoeconomics : Principles, Methods, And Applications, dalam: Chapter 1*. McGraw-Hill Global Education Holdings. LLC. China.

- Wahyuningsih, Mulyani. (2014). *Faktor Resiko Terjadinya Lesi Prakanker Serviks Melalui Deteksi Dini Dengan Metode IVA (Inspeksi Visual Dengan Asam Asetat)*. Department of Nutrition Faculty of Health Sciences, Esa Unggul University
- Watulingas, A., Loho, M. dan Wagey, F. (2016). Karakteristik penderita kanker serviks di RSUP Prof. Dr. R. D. Kandou Manado periode 1 Januari 2013 – 31 Desember 2015. *Jurnal e-Clinic (eCl)*, Volume 4, Nomor 2, Juli-Desember 2016.
- Wijayanti, N. W., et al. (2014). Analisis Efektifitas Biaya Pengobatan Kombinasi Amlodipin Furosemid Dibandingkan dengan Kombinasi Amlodipin Bisoprolol pada Pasien Hipertensi Rawat Jalan di Rsud Undata Palu Periode Agustus-Oktober Tahun 2014 Treatment Cost Effectiveness Analysis of The A, 5(1), 101–110.
- World Health Organization (WHO). *Angka Kesakitan Kanker*. Amerika: WHO; 2012.

